Originally Posted by
wco81
A study by the Univ. of British Columbia and the Karolinska Institutet in Stockholm show a drug previously tested for other types of lung disease can reduce the virus by a factor of 1000 to 5000 in lab conditions.
The drug is based on human recombinant soluble ACE2 or hrsACE2. The idea is to administer the drug in order to get the virus to bind to hrsACE2 rather than the ACE2 which line cells and other vital organs.
It should be noted that the lead UBC researcher Josef Penninger is the founder and shareholder of Aperion Biologics.
https://www.cathlabdigest.com/conten...an-cells-shows
Elsewhere, Penninger says there will be trials in Europe and results should be available in early summer:
Here is a pre-proof of the paper they're going to publish:
https://www.cell.com/pb-assets/produ...D-20-00739.pdf
I wasn't going to post this but given that Penninger has been brought up, I might as well. the BC CDC & UBC are going to hold a joint zoom symposium on COVID19 which includes the provincial health director Bonnie Henry (who's been our daily presser person) as well as Josef Penninger himself:
https://www.med.ubc.ca/research-2/vi...-19-symposium/
It starts in 30mins for anyone who's interested. It will touch on various topics as outlined in the program.
(Note that Josef Penninger is the Head of the Life Science Institute at UBC).